These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 8929158)

  • 21. Time between expanded disability status scale (EDSS) scores.
    Zurawski J; Glanz BI; Chua A; Lokhande H; Rotstein D; Weiner H; Engler D; Chitnis T; Healy BC
    Mult Scler Relat Disord; 2019 May; 30():98-103. PubMed ID: 30763908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alcohol, coffee, fish, smoking and disease progression in multiple sclerosis.
    D'hooghe MB; Haentjens P; Nagels G; De Keyser J
    Eur J Neurol; 2012 Apr; 19(4):616-24. PubMed ID: 22117611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of the 10-year direct costs for treating multiple sclerosis.
    Moccia M; Palladino R; Lanzillo R; Triassi M; Brescia Morra V
    Acta Neurol Scand; 2017 May; 135(5):522-528. PubMed ID: 27357245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disability progression in multiple sclerosis is slower than previously reported.
    Tremlett H; Paty D; Devonshire V
    Neurology; 2006 Jan; 66(2):172-7. PubMed ID: 16434648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium.
    Vaughn CB; Kavak KS; Dwyer MG; Bushra A; Nadeem M; Cookfair DL; Ramanathan M; Benedict RH; Zivadinov R; Goodman A; Krupp L; Motl RW; Weinstock-Guttman B;
    Mult Scler; 2020 Jan; 26(1):99-108. PubMed ID: 30507270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis.
    Ozakbas S; Cagiran I; Ormeci B; Idiman E
    J Neurol Sci; 2004 Mar; 218(1-2):3-7. PubMed ID: 14759626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis.
    Uitdehaag BMJ
    CNS Drugs; 2018 Jun; 32(6):543-558. PubMed ID: 29926371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disability profile of MS did not change over 10 years in a population-based prevalence cohort.
    Pittock SJ; Mayr WT; McClelland RL; Jorgensen NW; Weigand SD; Noseworthy JH; Rodriguez M
    Neurology; 2004 Feb; 62(4):601-6. PubMed ID: 14981177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hospitalization is associated with subsequent disability in multiple sclerosis.
    Garland A; Metz LM; Bernstein CN; Peschken CA; Hitchon CA; Marrie RA
    Mult Scler Relat Disord; 2017 May; 14():23-28. PubMed ID: 28619426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multimodal evoked potentials for functional quantification and prognosis in multiple sclerosis.
    Giffroy X; Maes N; Albert A; Maquet P; Crielaard JM; Dive D
    BMC Neurol; 2016 Jun; 16():83. PubMed ID: 27245221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erratum.
    Mult Scler; 2016 Oct; 22(12):NP9-NP11. PubMed ID: 26041800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Composite end points to assess delay of disability progression by MS treatments.
    Zhang J; Waubant E; Cutter G; Wolinsky J; Leppert D
    Mult Scler; 2014 Oct; 20(11):1494-501. PubMed ID: 24675040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A study validating changes in the multiple sclerosis functional composite.
    Hoogervorst EL; Kalkers NF; Uitdehaag BM; Polman CH
    Arch Neurol; 2002 Jan; 59(1):113-6. PubMed ID: 11790238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adherence to Web-Based Self-Assessments in Long-Term Direct-to-Patient Research: Two-Year Study of Multiple Sclerosis Patients.
    Jongen PJ; Kremer IEH; Hristodorova E; Evers SMAA; Kool A; van Noort EM; Hiligsmann M
    J Med Internet Res; 2017 Jul; 19(7):e249. PubMed ID: 28733272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis.
    Raffel J; Gafson AR; Dahdaleh S; Malik O; Jones B; Nicholas R
    PLoS One; 2017; 12(1):e0169546. PubMed ID: 28081190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis.
    Kallmann BA; Fackelmann S; Toyka KV; Rieckmann P; Reiners K
    Mult Scler; 2006 Feb; 12(1):58-65. PubMed ID: 16459720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference.
    Gavoille A; Rollot F; Casey R; Debouverie M; Le Page E; Ciron J; De Seze J; Ruet A; Maillart E; Labauge P; Zephir H; Papeix C; Defer G; Lebrun-Frenay C; Moreau T; Laplaud DA; Berger E; Stankoff B; Clavelou P; Thouvenot E; Heinzlef O; Pelletier J; Al Khedr A; Casez O; Bourre B; Cabre P; Wahab A; Magy L; Camdessanche JP; Maurousset A; Moulin S; Ben NH; Boulos DD; Hankiewicz K; Neau JP; Pottier C; Nifle C; Rabilloud M; Subtil F; Vukusic S;
    Neurology; 2023 Mar; 100(12):e1296-e1308. PubMed ID: 36564207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975-2009).
    Shirani A; Zhao Y; Kingwell E; Rieckmann P; Tremlett H
    Mult Scler; 2012 Apr; 18(4):442-50. PubMed ID: 21952097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The association of intrathecal production of immunoglobulin free light chains and progression of multiple sclerosis].
    Makshakov GS; Nazarov VD; Totolyan NA; Lapin SV; Mazing AV; Emanuel VL; Krasnov VS; Shumilina MV; Skoromets AA; Evdoshenko EP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10. Vyp. 2):4-10. PubMed ID: 29359727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study.
    Sartori A; Abdoli M; Freedman MS
    J Neurol; 2017 Jun; 264(6):1068-1075. PubMed ID: 28417192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.